Insilico Medicine and Luoxin Pharmaceuticals Forge Strategic AI-Driven R&D Alliance Targeting Digestive and Metabolic Disorders

Bulletin Express11-13 17:23

Insilico Medicine Cayman TopCo (“Insilico Medicine”) has signed a strategic cooperation agreement with Luoxin Pharmaceuticals Group Stock Co., Ltd. (“Luoxin Pharmaceuticals”, SZSE: 002793) to accelerate artificial-intelligence-powered drug discovery for digestive system, metabolic and other chronic, non-oncology diseases.

The partnership is structured as a long-term collaboration built on the principles of joint assessment, phased implementation and project-by-project confirmation. Both parties will combine Insilico Medicine’s AI drug-discovery platform with Luoxin Pharmaceuticals’ disease expertise, research data and development channels to identify novel therapeutic targets, design and optimize new molecules, and advance existing pipeline programs.

Key cooperation areas include: • Target identification and disease research. • Discovery and optimization of innovative molecules. • Translational research support for ongoing pipeline assets. • Technical and professional knowledge exchange.

Future expansion into additional disease areas is envisaged, subject to mutual agreement. Specific project details and financial terms will be defined in subsequent definitive agreements, and their execution remains uncertain.

The Board of Insilico Medicine emphasizes that all forward-looking statements are subject to risk, and shareholders and potential investors should exercise caution when dealing in the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162681358?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-11-13 17:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162681358","market":"hk","top_or_hot":-1,"title":"Insilico Medicine and Luoxin Pharmaceuticals Forge Strategic AI-Driven R&D Alliance Targeting Digestive and Metabolic Disorders","media":"Bulletin Express","content":"<p>Insilico Medicine Cayman TopCo (“Insilico Medicine”) has signed a strategic cooperation agreement with Luoxin Pharmaceuticals Group Stock Co., Ltd. (“Luoxin Pharmaceuticals”, SZSE: 002793) to accelerate artificial-intelligence-powered drug discovery for digestive system, metabolic and other chronic, non-oncology diseases.</p>\n<p>The partnership is structured as a long-term collaboration built on the principles of joint assessment, phased implementation and project-by-project confirmation. Both parties will combine Insilico Medicine’s AI drug-discovery platform with Luoxin Pharmaceuticals’ disease expertise, research data and development channels to identify novel therapeutic targets, design and optimize new molecules, and advance existing pipeline programs.</p>\n<p>Key cooperation areas include:\n• Target identification and disease research.  \n• Discovery and optimization of innovative molecules.  \n• Translational research support for ongoing pipeline assets.  \n• Technical and professional knowledge exchange.</p>\n<p>Future expansion into additional disease areas is envisaged, subject to mutual agreement. Specific project details and financial terms will be defined in subsequent definitive agreements, and their execution remains uncertain.</p>\n<p>The Board of Insilico Medicine emphasizes that all forward-looking statements are subject to risk, and shareholders and potential investors should exercise caution when dealing in the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insilico Medicine and Luoxin Pharmaceuticals Forge Strategic AI-Driven R&D Alliance Targeting Digestive and Metabolic Disorders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsilico Medicine and Luoxin Pharmaceuticals Forge Strategic AI-Driven R&D Alliance Targeting Digestive and Metabolic Disorders\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-11-13 17:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Insilico Medicine Cayman TopCo (“Insilico Medicine”) has signed a strategic cooperation agreement with Luoxin Pharmaceuticals Group Stock Co., Ltd. (“Luoxin Pharmaceuticals”, SZSE: 002793) to accelerate artificial-intelligence-powered drug discovery for digestive system, metabolic and other chronic, non-oncology diseases.</p>\n<p>The partnership is structured as a long-term collaboration built on the principles of joint assessment, phased implementation and project-by-project confirmation. Both parties will combine Insilico Medicine’s AI drug-discovery platform with Luoxin Pharmaceuticals’ disease expertise, research data and development channels to identify novel therapeutic targets, design and optimize new molecules, and advance existing pipeline programs.</p>\n<p>Key cooperation areas include:\n• Target identification and disease research.  \n• Discovery and optimization of innovative molecules.  \n• Translational research support for ongoing pipeline assets.  \n• Technical and professional knowledge exchange.</p>\n<p>Future expansion into additional disease areas is envisaged, subject to mutual agreement. Specific project details and financial terms will be defined in subsequent definitive agreements, and their execution remains uncertain.</p>\n<p>The Board of Insilico Medicine emphasizes that all forward-looking statements are subject to risk, and shareholders and potential investors should exercise caution when dealing in the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1162681358","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162681358","pubTimestamp":1794561828,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Insilico Medicine Cayman TopCo (“Insilico Medicine”) has signed a strategic cooperation agreement with Luoxin Pharmaceuticals Group Stock Co., Ltd. (“Luoxin Pharmaceuticals”, SZSE: 002793) to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"Insilico Medicine与罗欣药业建立人工智能驱动的战略研发联盟，瞄准消化和代谢紊乱","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"Insilico Medicine Cayman TopCo (“Insilico Medicine”) has signed a strategic cooperation agreement with Luoxin Pharmaceuticals Group Stock Co., Ltd. (“Luoxin Pharmaceuticals”, SZSE: 002793) to accelerate artificial-intelligence-powered drug discovery for digestive system, metabolic and other chronic, non-oncology diseases.\nThe partnership is structured as a long-term collaboration built on the principles of joint assessment, phased implementation and project-by-project confirmation. Both parties will combine Insilico Medicine’s AI drug-discovery platform with Luoxin Pharmaceuticals’ disease expertise, research data and development channels to identify novel therapeutic targets, design and optimize new molecules, and advance existing pipeline programs.\nKey cooperation areas include:\n• Target identification and disease research.  \n• Discovery and optimization of innovative molecules.  \n• Translational research support for ongoing pipeline assets.  \n• Technical and professional knowledge exchange.\nFuture expansion into additional disease areas is envisaged, subject to mutual agreement. Specific project details and financial terms will be defined in subsequent definitive agreements, and their execution remains uncertain.\nThe Board of Insilico Medicine emphasizes that all forward-looking statements are subject to risk, and shareholders and potential investors should exercise caution when dealing in the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162681358","isCrawlerRequest":true}